DBD Search
Irit Ben-Chelouche
Director of Business Development, Harvard Medical School
Displaying: 31 - 40 of 80 Results
Invention
Small molecule inhibitors of Ebola virus entry
Background: Human cells that are susceptible to infection by pathogenic viruses express surface membrane proteins that mediate attachment and membrane fusion activity of virus glycoproteins. There are strong structural and functional similarities…
Investigators
- Dennis Kasper
- Kyungae Lee
- Tao Ren
- James Cunningham
- Kartik Chandran
Invention
SPECT diagnostic agents for Parkinson’s Disease and ADHD
The Harvard research team has over two decades of experience in the design and synthesis of molecules that target monoamine uptake potently and selectively. The class of compounds utilized for the design of the subject SPECT agents is the…
Investigators
- Bertha Madras
- Paul Blundell
- Alan J. Fischman
- Peter Meltzer
- Alun G. Jones
- Ashfaq Mahmood
Invention
Novel target in NK cell mediated antigen specific memory responses
The von Andrian laboratory discovered a novel mechanism for inducing antigen specific immunological memory. Their research examines the role of a molecular target not previously known to be associated with the natural killer (NK) cell mediated…
Investigators
- Ulrich H. von Andrian
- Silke Paust
Invention
Directed evolution of proteins and nucleic acids using nonhomologous random recombination
The nonhomologous random recombination (NRR) method allows portions of nucleic acids to be recombined at sites where there is little or no sequence homology. This increases the frequency at which novel sequences are generated, allowing a more…
Investigators
- David R. Liu
- Joshua Bittker
Invention
Small-molecule macrocycles: Potent and selective Src kinase inhibitors
Macrocyclic compounds have unique properties that allow them to cover regions of chemical space not addressed by other small-molecule structural classes. By performing an in vitro selection screen of a broad untargeted DNA-encoded library of 13,824…
Investigators
- David R. Liu
- Ralph Elliot Kleiner
Invention
Bisphosphonates as novel adjuvants to enhance the adaptive immune response, validated with common types of vaccine antigens and commercial vaccines
Despite decades of adjuvant research, only a handful of adjuvants have been approved in seven major global markets and only two (Alum and GSK’s AS04) are licensed in the US. The availability of additional adjuvants has been minimized due to…
Investigators
- Ulrich H. von Andrian
- Matteo Iannacone
- Elena Tonti
- Elliott Ashley Moseman
Invention
Small-molecule-triggered intein splicing as a universal switch for protein activation
Researchers in the laboratory of Professor David Liu have used directed evolution techniques to evolve an intein-based molecular switch that transduces binding of a small molecule into the activation of an arbitrary protein of interest. To create…
Investigators
- David R. Liu
- Allen R. Buskirk
- Sun H. Peck
Invention
Novel methods for generating regulatory T-cells
Regulatory T-cells (Tregs) are key mediators of peripheral tolerance that can actively suppress effector T-cells, inhibit inflammation and mediate self-tolerance. Unlike naturally occurring Tregs (nTregs) which develop in the thymus,…
Investigators
- Arlene H. Sharpe
- Loise Francisco
- Vijay K. Kuchroo
Invention
Drug-inducible RNA aptaswitch for regulating eukaryotic protein expression
Using in vivo evolution techniques, scientists in the Liu laboratory have engineered a drug-inducible aptaswitch for regulating eukaryotic protein expression at the transcription level. This aptaswitch consists of two modular RNA elements: a…
Investigators
- David R. Liu
- Allen R. Buskirk
- Polina Kehayova
Invention
Fzd2 - novel anti-cancer therapeutic target
The role of β-catenin accumulation in the development of tumorigenicity has been well documented to date, with various mutations in β-catenin, APC, and axin genes typically to blame. Although β-catenin accumulation plays a role in hepatocellular…
Investigators
- Gavin MacBeath
- Taran S. Gujral